Virbac (CHIX:VIRPP) Tariff Resilience Score: 6/10 (As of Jul. 11, 2026)


CHIX:VIRPP Virbac SA CHIX:VIRPP
95 GF Score
Price €334.00
GF Value €384.96
! 2 Warning Signs
View Full Analysis

What is Virbac Tariff Resilience Score?

Virbac CHIX:VIRPP 95 Tariff Resilience Score is 6 as of Jul. 11, 2026. GuruFocus rates CHIX:VIRPP with a GF Score™ of 95/100 and a GF Value™ of €384.96. The stock has 2 warning signs investors should review. Among 1,029 Drug Manufacturers companies, Virbac ranks better than 91.06% on this metric.

Virbac has the Tariff Resilience Score of 6, which implies that the company might have Average Resilient.

Virbac has Global animal health company with diverse manufacturing locations. While exposed to tariffs, it has a balanced import/export profile and can adjust sourcing strategies.

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes Virbac might have Average Resilient.

Virbac  (CHIX:VIRPp) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

Virbac Tariff Resilience Score Related Terms

CHIX:VIRPP vs LLY, JNJ, ABBV: Tariff Resilience Score Comparison

For the Drug Manufacturers - General subindustry, Virbac's Tariff Resilience Score, along with its competitors' market caps and Tariff Resilience Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Virbac Tariff Resilience Score vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Virbac's Tariff Resilience Score distribution charts can be found below:

* The bar in red indicates where Virbac's Tariff Resilience Score falls into.


CHIX:VIRPP
95GF Score
Virbac SA CHIX:VIRPP
Tariff Resilience Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Tariff Resilience Score of 6 mean?
Virbac (CHIX:VIRPP) has a Tariff Resilience Score of 6 as of Jul. 11, 2026. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. According to the industry distribution chart, Virbac ranks #92 out of 1029 companies in the Drug Manufacturers industry, placing it in the top 8.9%.
Is Virbac's Tariff Resilience Score too high?
Virbac's current Tariff Resilience Score is 6. Based on the distribution chart, Virbac ranks #92 out of 1029 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Virbac has a GF Score™ of 95/100, reflecting its overall financial health beyond just this single metric.
How does Virbac's Tariff Resilience Score compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Virbac ranks #92 out of 1029 companies for Tariff Resilience Score. This places Virbac in the top 9% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tariff Resilience Score for a Drug Manufacturers company?
A good Tariff Resilience Score depends on the Drug Manufacturers industry context. However, Tariff Resilience Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tariff Resilience Score mean?
A high Tariff Resilience Score can signal that a stock is expensive relative to its fundamentals. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. Virbac's current Tariff Resilience Score is 6. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Virbac stock overvalued right now?
Virbac (CHIX:VIRPP) has a current Tariff Resilience Score of 6. The stock's GF Value™ is €384.96, compared to a current price of €334.00 — trading 13.2% below its estimated fair value. The current Tariff Resilience Score is 6. Virbac's overall GF Score™ is 95/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tariff Resilience Score calculated?
Tariff Resilience Score is calculated from a company's financial statements. For Virbac (CHIX:VIRPP), the current Tariff Resilience Score is 6 as of Jul. 11, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Virbac (CHIX:VIRPP) Overvalued in 2026?

Based on GuruFocus' analysis, Virbac stock appears to be undervalued. The current stock price of €334.00 is trading 13.2% below its estimated GF Value™ of €384.96.

Key valuation signals for CHIX:VIRPP:

  • Tariff Resilience Score: 6
  • GF Value™: €384.96 vs. price of €334.00 (13.2% below fair value)
  • GF Score™: 95/100 with 2 warning signs

No single metric tells the full story. See the CHIX:VIRPP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Virbac Business Description

Address 13e rue, 1ere avenue 2065, LID - BP 27, Carros, FRA, 06511
Virbac SA is a drug manufacturing company with a focus on animal health. The company generates the vast majority of its revenue in Europe, and it also has its presence in Europe, North America, Far East Asia, India, Africa & Middle East (IMEA), Pacific, and Latin America.
95GF Score

Get the complete analysis for CHIX:VIRPP

Tariff Resilience Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€334.00
Price
€384.96
GF Value